Smith & Nephew Endoscopy Announces Availability of TRUCLEAR(TM) Hysteroscopic Morcellator at the AAGL Annual Meeting
17 November 2009 - 11:55AM
PR Newswire (US)
Innovative System Allows for Efficient Removal of Intrauterine
Polyps and Fibroids ANDOVER, Mass., Nov. 17 /PRNewswire-FirstCall/
-- Smith & Nephew's (NYSE: SNN)(LSE:SN) Endoscopy Division
announced the launch of the TRUCLEAR(TM) System, an operative
hysteroscopy device, which is now widely available in the United
States. In conjunction with the announcement, Smith & Nephew
will host a panel discussion today about hysteroscopy at this
year's American Association of Gynecologic Laparoscopists (AAGL)
annual meeting, which is being held in Orlando, Fla. The inventor
of the TRUCLEAR System, Mark Hans Emanuel, M.D., Department of
Obstetrics and Gynecology, Spaarne Hospital, The Netherlands, will
chair the panel discussion. The TRUCLEAR System is a first-of-its
kind device that enables a fast and thorough capture and removal of
intrauterine polyps and fibroids, and provides healthcare
practitioners in obstetrics and gynecology and reproductive health
with a uniquely user-friendly technique. The system pairs the
visualization capabilities of a hysteroscope with the tissue
removal capabilities of a morcellator, allowing healthcare
practitioners a quick capture and removal of polyps and fibroids.
"The availability of the TRUCLEAR System provides healthcare
practitioners a safe and much-needed option for the half a million
women in the United States who seek treatment for intrauterine
polyps and fibroids," said Mira Sahney, Director of Gynecology at
Smith & Nephew Endoscopy. "Current treatments pose significant
challenges, ranging from using electricity in the uterus to
obstructed visibility. With the TRUCLEAR System, clarity is
uncompromised and the uterus remains intact, so that practitioners
can focus on efficiently and safely treating their patients." The
TRUCLEAR System was designed to overcome the primary challenges
with current treatments. The system, which has a four-year safety
record, is optimized to thoroughly remove tissue so that physicians
are not required to make multiple, time-consuming insertions into
the uterine cavity, thereby reducing the risks of uterine damage.
It cleanly removes tissue from the uterine cavity, leaving the
hysteroscopic view unobscured and ultimately allows healthcare
practitioners greater clarity to complete a given procedure.
Moreover, unlike other treatment options that use a high-frequency
electric current, the TRUCLEAR System uses a simple mechanical
approach, so that patients are not at risk of damage from internal
and external burns caused by uncontrolled leakage of current. "I
use Smith & Nephew's hysteroscopic morcellator for all my
polypectomy procedures, as do all of my colleagues," said Seine
Chiang, M.D., Seattle, Wash. "The process of removing polyps has
been greatly simplified with the TRUCLEAR System." Prior to its
wide availability, the TRUCLEAR System received a high satisfaction
rating among obstetricians and gynecologists who participated in a
pilot program of the technology. Given the enthusiasm among these
early adopters for the surgical device's advantages in a clinical
setting, Smith & Nephew Endoscopy is beginning to market the
TRUCLEAR System broadly to obstetrics and gynecology practitioners,
as well as reproductive health specialists. Additional information
on the TRUCLEAR System and Smith & Nephew's activities at AAGL
can be obtained by following the company's Twitter feed at
http://twitter.com/smithnephewGYN (TM) Trademark of Smith &
Nephew About Smith & Nephew Smith & Nephew is a global
medical technology business, specializing in Orthopaedics,
including Reconstruction, Trauma and Clinical Therapies; Endoscopy
and Advanced Wound Management. Smith & Nephew is a global
leader in arthroscopy and advanced wound management and is one of
the leading global orthopaedics companies. Smith & Nephew is
dedicated to helping improve people's lives. The Company prides
itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous
with high standards of performance, innovation and trust. The
Company operates in 32 countries around the world. Annual sales in
2008 were nearly $3.8 billion. Forward-Looking Statements This
press release contains certain "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. In particular, statements regarding planned growth in our
business and in our operating margins discussed under "Outlook" are
forward-looking statements as are discussions of our product
pipeline. These statements, as well as the phrases "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions, are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors (including, but not
limited to, the outcome of litigation and regulatory approvals)
that could cause the actual results, performance or achievements of
Smith & Nephew, or industry results, to differ materially from
any future results, performance or achievements expressed or
implied by such forward-looking statements. Please refer to the
documents that Smith & Nephew has filed with the U.S.
Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith & Nephew's
most recent annual report on Form 20F, for a discussion of certain
of these factors. All forward-looking statements in this press
release are based on information available to Smith & Nephew as
of the date hereof. All written or oral forward-looking statements
attributable to Smith & Nephew or any person acting on behalf
of Smith & Nephew are expressly qualified in their entirety by
the foregoing. Smith & Nephew does not undertake any obligation
to update or revise any forward-looking statement contained herein
to reflect any change in Smith & Nephew's expectation with
regard thereto or any change in events, conditions or circumstances
on which any such statement is based. Contact: Joe Metzger SVP,
Corporate Communications Smith & Nephew Endoscopy (978)
749-1330 DATASOURCE: Smith & Nephew CONTACT: Joe Metzger, SVP,
Corporate Communications of Smith & Nephew Endoscopy,
+1-978-749-1330,
Copyright